Bang yj et al. lancet 2010 376: 687-697
웹2013년 10월 24일 · Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.Lancet. 2010;376(9742):687-697. 웹2024년 3월 23일 · Lancet. 2010; 376: 687-697. Summary; Full Text; Full Text PDF; PubMed; Scopus (5240) Google Scholar, 7. Hecht JR ; Bang YJ ; Qin SK ; et al. Lapatinib in …
Bang yj et al. lancet 2010 376: 687-697
Did you know?
웹2024년 4월 12일 · Lancet 376:687–697 CrossRef Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697 CrossRef 웹2024년 6월 28일 · randomized controlled trial in 2010 (Trastuzumab for Gastric Cancer ... Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy ... gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet. 2010;376(9742):687-697. 7. Hofmann . M, Stoss O ...
웹2024년 6월 23일 · Lancet. 2010; 376: 687-697. Summary; Full Text; Full Text PDF; PubMed; Scopus (5240) ... Bang YJ ; et al. Pembrolizumab versus paclitaxel for previously treated, … 웹2024년 3월 23일 · Bang YJ ; Van Cutsem E ; Feyereislova A ; et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer ... Lancet. 2010; 376: 687-697. Summary; Full Text; Full Text PDF; PubMed; Scopus (5240) Google Scholar;
웹Lancet 376:687–697 CrossRefPubMed Bang YJ, Van CE, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376:687–697 CrossRef PubMed 웹Bang YJ, Van Cutsem E, Feyereislova A, et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [published correction appears in Lancet . 2010;376(9749):1302].
웹2024년 9월 25일 · Lancet. 2010; 376: 687-697. Summary; Full Text; Full Text PDF; PubMed; Scopus (4937) Google Scholar; ... Bang YJ ; Lordick F ; et al. Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: the METGastric randomized clinical trial.
웹2010년 8월 28일 · Background: Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2; also known as ERBB2), was investigated in … free business domain hosting웹Lancet 376:687–697 CrossRefPubMed Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. block horneado웹2015년 5월 5일 · Cochrane Database Syst Rev. 2010;(3):CD004064. 18. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. … free business email accounts gmx mail웹Für die HER2-gerichtete Therapie ist der Nachweis einer Rezeptor-Überexpression und/oder der Genamplifikation mittels In-situ-Hybridisierung (ISH) block host.cmd웹Bang YJ, et al. Lancet 2010;376:687–697. 胃癌和胃食管交界癌的HER2 检测推荐流程 患者肿瘤样本 IHC 0 1+ 2+ ISH 3+ – + 需要进行曲妥珠单抗治疗 《胃癌HER2检测指南》编写组 … block horst mountain웹Methods/Design: This single-center study was designed to combine low-dose apatinib with camrelizumab plus the SOX regimen in diagnosed potentially resectable and initially unresectable AGC/GEJC. This a prospective, open-label, single-arm, dose escalation and extension phase Ib clinical trial, conducted in Jiangsu Province Hospital, beginning ... block hoofd웹2010년 8월 20일 · et al. Global cancer facts and figures 2007. ... Bang Y-J, Van Cutsem E, Feyereislova A, et al, ... (ToGA): a phase 3, open-label, randomised controlled trial. Lancet … block host.cmd دانلود